Pharma News, 2019

Pandion Therapeutics has signed a license and collaboration deal worth up to $795m with Japan-based Astellas Pharma to research, develop, and commercialise locally acting immunomodulators for autoimmu...

The transition from egg-based towards cell-based, recombinant and universal influenza vaccines will drive growth in the seasonal influenza vaccine market, a report has said.

PARIS - November 4, 2019 – The U.

TEL-AVIV, Israel and RALEIGH, N.

GV-971 is a seaweed-based drug which can improve cognitive ability in people suffering from mild-to-moderate Alzheimer’sA homegrown drug for treating Alzheimer’s disease has been approved by China...

Dr.

ZURICH (Reuters) - U.

PRAC recommends measures to minimise risk of serious side effects with Lemtrada for multiple sclerosisEMA’s safety committee (PRAC) recommended restricting Lemtrada for use in adults with re...

Dicerna Pharmaceuticals has signed a research collaboration and licensing agreement with Roche to create treatments for chronic hepatitis B virus (HBV) infection.

THOUSAND OAKS, Calif.

With drugmakers like Pfizer expanding their cell and gene therapy operations, recombinant protein producer Bio-Techne says it needs a new plant to keep up with demand.

CAMBRIDGE, Mass.